Journal ArticleDOI
Dexamethasone Intravitreal Implant in Patients with Macular Edema Related to Branch or Central Retinal Vein Occlusion: Twelve-Month Study Results
Julia A. Haller,Francesco Bandello,Rubens Belfort,Mark S. Blumenkranz,Mark C Gillies,Jeffrey S. Heier,Anat Loewenstein,Young Hee Yoon,Jenny Jiao,Xiao-yan Li,Scott M. Whitcup +10 more
Reads0
Chats0
TLDR
Among patients with macular edema owing to BRVO or CRVO, single and repeated treatment with DEX implant had a favorable safety profile over 12 months.About:
This article is published in Ophthalmology.The article was published on 2011-12-01. It has received 632 citations till now. The article focuses on the topics: Macular edema & Dexamethasone Intravitreal Implant.read more
Citations
More filters
Journal ArticleDOI
Mechanisms of macular edema: Beyond the surface.
Alejandra Daruich,Alexandre Matet,Alexandre Moulin,Laura Kowalczuk,Michael Nicolas,Alexandre Sellam,Pierre-Raphaël Rothschild,Samy Omri,Emmanuelle Gelize,Laurent Jonet,Kimberley Delaunay,Yvonne de Kozak,Marianne Berdugo,Min Zhao,Patricia Crisanti,Francine Behar-Cohen,Francine Behar-Cohen +16 more
TL;DR: This comprehensive review on the current understanding of macular edema and its mechanisms opens perspectives to identify new preventive and therapeutic strategies for this sight-threatening condition.
Journal ArticleDOI
Intravitreal Aflibercept for Macular Edema Following Branch Retinal Vein Occlusion: 52-Week Results of the VIBRANT Study
Peter A. Campochiaro,W. Lloyd Clark,David S. Boyer,Jeffrey S. Heier,David M. Brown,Robert Vitti,Husain Kazmi,Alyson J. Berliner,Erickson Kristine A,Karen W. Chu,Yuhwen Soo,Yenchieh Cheng,Julia A. Haller +12 more
TL;DR: The VIBRANT trial as discussed by the authors showed that 2 mg intravitreal aflibercept injection (IAI) compared with grid laser was effective in controlling macular edema.
Journal ArticleDOI
A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX study.
Mark C Gillies,Lyndell L Lim,Anna Campain,Godfrey J. Quin,Wedad Salem,Ji Li,Stephanie Goodwin,Christine Aroney,Ian L. McAllister,Samantha Fraser-Bell +9 more
TL;DR: In this article, the authors reported the 12-month results of the first head-to-head comparison of a dexamethasone implant (Ozurdex; Allergan, Inc., Irvine, CA) versus bevacizumab (Avastin; Genentech, South San Francisco, CA).
Journal ArticleDOI
Intravitreal Aflibercept Injection for Macular Edema Due to Central Retinal Vein Occlusion: Two-Year Results from the COPERNICUS Study
Jeffrey S. Heier,W. Lloyd Clark,David S. Boyer,David M. Brown,Robert Vitti,Alyson J. Berliner,Husain Kazmi,Yu Ma,Brigitte Stemper,Brigitte Stemper,Oliver Zeitz,Rupert Sandbrink,Rupert Sandbrink,Julia A. Haller +13 more
TL;DR: In this paper, the authors evaluated the efficacy and safety of intravitreal aflibercept injection (IAI) for the treatment of macular edema secondary to central retinal vein occlusion (CRVO).
Journal ArticleDOI
Ocular Drug Delivery: Present Innovations and Future Challenges.
TL;DR: Novel drug-delivery technologies, including nanoparticles, nanomicelles, dendrimers, microneedles, liposomes, and nanowafers, are increasingly studied for anterior and posterior disorders.
References
More filters
Journal ArticleDOI
Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study.
David M. Brown,Peter A. Campochiaro,Rishi P. Singh,Zhengrong Li,Sarah Gray,Namrata Saroj,Amy Chen Rundle,Roman G. Rubio,Wendy Yee Murahashi +8 more
TL;DR: Intraocular injections of 0.3 mg or 0.5 mg ranibizumab provided rapid improvement in 6-month visual acuity and macular edema following CRVO, with low rates of ocular and nonocular safety events.
Journal ArticleDOI
Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion.
Julia A. Haller,Francesco Bandello,Rubens Belfort,Mark S. Blumenkranz,Mark C Gillies,Jeffrey S. Heier,Anat Loewenstein,Young-Hee Yoon,Marie-Louise Jacques,Jenny Jiao,Xiao-yan Li,Scott M. Whitcup +11 more
TL;DR: In this paper, the safety and efficacy of dexamethasone intravitreal implant (DEX implant; OZURDEX, Allergan, Inc., Irvine, CA) compared with sham in eyes with vision loss due to macular edema (ME) associated with BRVO or central retinal vein occlusion (CRVO).
Journal ArticleDOI
Ranibizumab for Macular Edema following Branch Retinal Vein Occlusion
Peter A. Campochiaro,Jeffrey S. Heier,Leonard Feiner,Sarah Gray,Namrata Saroj,Amy Chen Rundle,Wendy Yee Murahashi,Roman G. Rubio +7 more
TL;DR: Intraocular injections of 0.3 mg or 0.5 mg ranibizumab provided rapid, effective treatment for macular edema following BRVO with low rates of ocular and nonocular safety events and no new safety events were identified in patients with BRVO.
Journal ArticleDOI
A Randomized Trial Comparing the Efficacy and Safety of Intravitreal Triamcinolone With Observation to Treat Vision Loss Associated With Macular Edema Secondary to Central Retinal Vein Occlusion: The Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) Study Report 5
Michael S. Ip,Ingrid U. Scott,Paul C. VanVeldhuisen,Neal Oden,Barbara A Blodi,Marian R. Fisher,Lawrence J. Singerman,Michael J. Tolentino,Clement K. Chan,Victor H. Gonzalez +9 more
TL;DR: Intravitreal triamcinolone is superior to observation for treating vision loss associated with macular edema secondary to CRVO in patients who have characteristics similar to those in the SCORE-CRVO trial.
Journal ArticleDOI
Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema.
Baruch D. Kuppermann,Mark S. Blumenkranz,Julia A. Haller,George A. Williams,David V. Weinberg,Connie Chou,Scott M. Whitcup +6 more
TL;DR: In persistent macular edema, a single dexamethasone DDS treatment produced statistically significant BCVA improvements 90 days after treatment and was well tolerated for 180 days.